"Patient-reported outcomes in futibatinib-treated intrahepatic cholangiocarcinoma patients with fgfr2 fusions/rearrangements: results from the foenix-CCA2 study "
Epstein, R. S.
Valle, Juan W
AffiliationUCL Cancer Institute, London, UK
MetadataShow full item record
AbstractWe report patient-reported outcomes (PROs) results from the pivotal phase 2 trial FOENIX-CCA2 (NCT02052778). FOENIX-CCA2 evaluated futibatinib, an irreversible FGFR1–4 inhibitor, among intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions/rearrangements. Futibatinib demonstrated a confirmed objective response rate of 41.7%; adverse events were manageable. PROs were a prespecified secondary objective of the study.
CitationBridgewater, J A, Hollebecque, A, Furuse, J, Goyal, L, Meric-Bernstam, F, Epstein, R S, Morlock, R, Salimi, T, Wacheck, V, Liu, M, Benhadji, K, Valle, Juan W. "Patient-reported outcomes in futibatinib-treated intrahepatic cholangiocarcinoma patients with fgfr2 fusions/rearrangements: results from the foenix-CCA2 study. Value in Health . 2022
JournalValue in Health
TypeMeetings and Proceedings